CClinicalTrials.gg
Not yet recruitingNCT07798934Updated Sep 2, 2026

Effect of White Noise on Salivary Cortisol and Vital Signs During Gastroscopy

An interventional study of White Noise in Procedural Anxiety and Physiological Stress, sponsored by Yuzuncu Yil University. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-02.

Sponsored by Yuzuncu Yil University · Not applicable, Interventional, and Supportive care

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This randomized controlled trial aims to determine whether white noise affects salivary cortisol levels and vital signs in adult patients undergoing gastroscopy. Participants will be randomly assigned to either a white noise group or a control group receiving routine care. Patients in the intervention group will listen to white noise in accordance with the study protocol. Saliva samples will be collected to assess cortisol levels, and vital signs will be measured at predetermined time points. The results of the two groups will be compared to evaluate whether white noise helps reduce the physiological stress response associated with gastroscopy.

Read the detailed description

Gastroscopy may cause procedural stress due to uncertainty, swallowing of the endoscope, the gag reflex, and environmental noise. This stress may activate the sympathetic nervous system and the hypothalamic-pituitary-adrenal axis, resulting in changes in vital signs and increased cortisol secretion. White noise is a non-pharmacological intervention that may mask environmental sounds and reduce auditory stimulation. However, evidence regarding its effect on an objective biochemical stress marker in patients undergoing gastroscopy under sedation remains limited.

This single-center randomized controlled trial will include 100 adult patients scheduled for elective diagnostic gastroscopy under sedation. Participants will be assigned to the white noise intervention group or the routine care control group using computer-generated block randomization, with 50 participants planned for each group. Before sedation, demographic and clinical information will be collected, baseline vital signs will be recorded, and participants will rate their anxiety and pain using 0-10 visual analog scales. A baseline saliva sample will then be collected for cortisol measurement.

Participants assigned to the intervention group will begin listening to white noise through headphones with disposable protective covers immediately before entering the endoscopy room, while they are still awake. The intervention will continue without interruption during sedation induction and throughout the gastroscopy procedure. Participants in the control group will receive routine care without an auditory intervention. Vital signs, including systolic and diastolic blood pressure, heart rate, respiratory rate, and oxygen saturation, will be recorded at baseline, during the fifth minute of the procedure, and during recovery.

The white noise intervention will be discontinued when the procedure is completed. Anxiety and pain will be reassessed after the procedure. A second saliva sample will be collected approximately 20-30 minutes after the procedure to account for the expected salivary cortisol response. Saliva samples will be maintained under appropriate cold-chain conditions and stored until cortisol concentrations are measured using an enzyme-linked immunosorbent assay. Changes in salivary cortisol, vital signs, anxiety, and pain will be compared between the intervention and control groups.

02

Conditions studied

  • Procedural Anxiety
  • Physiological Stress

Keywords

  • White Noise
  • Gastroscopy
  • Salivary Cortisol
  • Vital Signs
  • Procedural Anxiety
  • Physiological Stress
  • Nursing Intervention
  • Randomized Controlled Trial
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Aged 18 years or older
  • Scheduled for elective diagnostic gastroscopy under sedation
  • Able to communicate in Turkish
  • Able to hear the white noise intervention and without hearing loss that would prevent its use
  • Willing to participate voluntarily and able to provide written informed consent

Exclusion criteria

Exclusion Criteria:

  • Undergoing emergency gastroscopy
  • Diagnosed psychiatric disorder or current use of psychotropic medication that may affect anxiety
  • Hearing impairment that would prevent effective delivery of the white noise intervention
  • Use of systemic, topical, or inhaled glucocorticoids within the previous month
  • Diagnosed adrenal or pituitary gland disorder
  • Pregnant or breastfeeding
  • Active oral lesions, gingival bleeding, or severe periodontitis that may compromise saliva sample quality
  • Smoking or consumption of caffeinated beverages within two hours before the procedure
04

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    White Noise Intervention Group

    Participants will receive routine care and listen to white noise through headphones beginning immediately before entering the endoscopy room. White noise will continue uninterrupted during sedation induction and throughout the gastroscopy procedure and will be discontinued when the procedure is completed.

    Behavioral: White Noise

  • No intervention
    Routine Care Control Group

    Participants will receive routine care provided by the endoscopy unit without any auditory intervention during the gastroscopy procedure.

Interventions

  • BehavioralWhite Noise

    White noise will be delivered through headphones with disposable protective covers, beginning immediately before the participant enters the endoscopy room and continuing uninterrupted during sedation induction and throughout the gastroscopy procedure.

05

What researchers measure

Primary outcomes

  1. Change in Salivary Cortisol Level

    Salivary cortisol concentration will be measured using an enzyme-linked immunosorbent assay (ELISA). The change from baseline will be calculated by subtracting the pre-procedure cortisol concentration from the post-procedure concentration and compared between the white noise and routine care groups. Higher cortisol concentrations indicate a greater physiological stress response.

    Time frame: Perioperative and Periprocedural

Secondary outcomes

  1. Change in Systolic Blood Pressure

    Systolic blood pressure will be measured in millimeters of mercury (mmHg). Changes from the pre-procedure baseline will be compared between the white noise and routine care groups.

    Time frame: Perioperative and Periprocedural

  2. Change in Diastolic Blood Pressure

    Diastolic blood pressure will be measured in millimeters of mercury (mmHg). Changes from the pre-procedure baseline will be compared between the white noise and routine care groups.

    Time frame: Perioperative and Periprocedural

  3. Change in Heart Rate

    Heart rate will be measured in beats per minute. Changes from the pre-procedure baseline will be compared between the white noise and routine care groups.

    Time frame: Perioperative and Periprocedural

  4. Change in Respiratory Rate

    Respiratory rate will be measured in breaths per minute. Changes from the pre-procedure baseline will be compared between the white noise and routine care groups.

    Time frame: Perioperative and Periprocedural

  5. Change in Peripheral Oxygen Saturation

    Peripheral oxygen saturation will be measured as a percentage using pulse oximetry. Changes from the pre-procedure baseline will be compared between the white noise and routine care groups. Higher percentages indicate greater oxygen saturation.

    Time frame: Perioperative and Periprocedural

  6. Change in Patient-Reported Anxiety

    Anxiety will be assessed using a 10-centimeter Visual Analog Scale ranging from 0 to 10, where 0 indicates no anxiety and 10 indicates the worst possible anxiety. The change from the pre-procedure score to the post-procedure score will be compared between groups.

    Time frame: Perioperative and Periprocedural

  7. Change in Patient-Reported Pain

    Pain will be assessed using a 10-centimeter Visual Analog Scale ranging from 0 to 10, where 0 indicates no pain and 10 indicates the worst possible pain. The change from the pre-procedure score to the post-procedure score will be compared between groups.

    Time frame: Perioperative and Periprocedural

06

Study locations

No study locations are listed for this record.

07

References and documents

Publications

  • Sogabe M, Okahisa T, Fukuya A, Kagemoto K, Okada Y, Adachi Y, Kurihara T, Nii T, Teramae S, Tanaka H, Tomonari T, Okamoto K, Miyamoto H, Nakasono M, Takayama T. Effects of audio and visual distraction on patients' vital signs and tolerance during esophagogastroduodenoscopy: a randomized controlled trial. BMC Gastroenterol. 2020 Apr 21;20(1):122. doi: 10.1186/s12876-020-01274-3. PubMed 32316918 ↗
  • Demirci S, Sezer S. Effect of Binaural Beats on Anxiety and Tolerance in Patients Undergoing Upper Gastrointestinal Endoscopy Without Sedation: A Randomized Controlled Trial. J Integr Complement Med. 2024 Dec;30(12):1209-1216. doi: 10.1089/jicm.2023.0804. Epub 2024 Aug 1. PubMed 39088370 ↗
  • Genc H, Tanriverdi S. The Effects of a Portative Glass Waterfall and a White Noise App On Pain, Anxiety, and Physiological Parameters During Gastroscopy. Pain Manag Nurs. 2026 Feb;27(1):e103-e111. doi: 10.1016/j.pmn.2025.10.001. Epub 2025 Oct 22. PubMed 41130873 ↗

Individual participant data

Plan to share: No

08

Registry details

Key details

Study ID
NCT07798934
Lead sponsor
Yuzuncu Yil University
Collaborators
Van Yüzüncü Yıl University Scientific Research Projects Coordination Unit
Responsible party
Zeynep Gürkan (Research Assistant, PhD, Yuzuncu Yil University) — Principal investigator
First posted
Sep 2, 2026
Start date
Sep 27, 2026 (estimated)
Primary completion
Feb 15, 2027 (estimated)
Completion
Feb 15, 2027 (estimated)
Last update
Sep 2, 2026

Study contacts

Zeynep GÜRKAN, PhD
Contact
zeynepgurkan@yyu.edu.tr
+905389786500

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion